Dr. Kerry Culm-Merdek of Oncologie and Dr. Marian Navratil of HTG Molecular Diagnostics will describe their cross-platform comparison study between RNA-Seq and HTG’s translational research profiling panel, the HTG EdgeSeq Precision Immuno-Oncology Panel (PIP) for measuring gene expression.
Read the HTG customer posters presented at ASCO 2020
EMD Serono’s Dr. O’Rourke, et. al. presents comparison of
HTG EdgeSeq technology
Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens.
Virtual Podium presentation by Dr. James Cooley. Register now!
Presentation Background: Diffuse large B-cell lymphoma (DLBCL) is the most common NHL in adults. Gene expression profiling (GEP) divides DLBCL according to the cell of origin (COO) into three subgroups: GCB, ABC and unclassifiable (UNC), exhibiting different mutational profiles.
Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment – Implication for Therapeutic Benefit in the Immunotherapy Era
Renal cell carcinoma (RCC) with sarcomatoid features (sRCC) is an aggressive form of RCC with poor response to conventional therapies. Immune checkpoint inhibitors have shown promising therapeutic effect for sRCC in recent small series and sRCC has demonstrated higher PD-L1 expression and PD-1 positive tumor-infiltrating lymphocytes compared to high-grade clear cell RCC (ccRCC). Our aim was to use multiplexed gene expression assays to gain a broader view of the underlying tumor microenvironment in sRCC.
HTG presentation on the Methods and Challenges of Quantitative miRNA Profiling
Join HTG at the 15th Annual Biomarkers Congress along with our guest speaker, Dr. Megan Lloyd, University of Southampton Academic Unit of Cancer Sciences
Meet us in Long Branch, NJ for the 2019 BMS R&D Symposium!
Join HTG at the 5th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference
Page last updated September 29, 2020